Comparative biochemical analysis of HIV-1 subtype B and C integrase enzymes

被引：40

作者：

Bar-Magen, Tamara ^{[1
]}

Sloan, Richard D. ^{[1
]}

Faltenbacher, Verena H. ^{[1
]}

Donahue, Daniel A. ^{[1
,2
]}

Kuhl, Bjoern D. ^{[1
,3
]}

Oliveira, Maureen ^{[1
]}

Xu, Hongtao ^{[1
]}

Wainberg, Mark A. ^{[1
,2
,3
]}

机构：

[1] McGill Univ, AIDS Ctr, Lady Davis Inst, Jewish Gen Hosp, Montreal, PQ, Canada

[2] McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3A 2T5, Canada

[3] McGill Univ, Div Expt Med, Montreal, PQ H3A 2T5, Canada

来源：

RETROVIROLOGY | 2009年 / 6卷

基金：

加拿大健康研究院;

关键词：

DNA INTEGRATION; STRAND-TRANSFER; IN-VITRO; VIRUS; RESISTANCE; RALTEGRAVIR; PROTEIN; INHIBITORS; MUTATIONS; ELVITEGRAVIR;

D O I：

10.1186/1742-4690-6-103

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Background: Integrase inhibitors are currently being incorporated into highly active antiretroviral therapy (HAART). Due to high HIV variability, integrase inhibitor efficacy must be evaluated against a range of integrase enzymes from different subtypes. Methods: This study compares the enzymatic activities of HIV-1 integrase from subtypes B and C as well as susceptibility to various integrase inhibitors in vitro. The catalytic activities of both enzymes were analyzed in regard to each of 3' processing and strand transfer activities both in the presence and absence of the integrase inhibitors raltegravir (RAL), elvitegravir (EVG), and MK-2048. Results: Our results show that integrase function is similar with enzymes of either subtype and that the various integrase strand transfer inhibitors (INSTIs) that were employed possessed similar inhibitory activity against both enzymes. Conclusion: This suggests that the use of integrase inhibitors against HIV-1 subtype C will result in comparable outcomes to those obtained against subtype B infections.

引用

页数：10

共 32 条

[21] Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants [J].

Marinello, Jessica ;

Marchand, Christophe ;

Mott, Bryan T. ;

Bain, Anjali ;

Thomas, Craig J. ;

Pommier, Yves .

BIOCHEMISTRY, 2008, 47 (36) :9345-9354

[22] Differences in resistance mutations among HIV-1 non-subtype B infections: a systematic review of evidence (1996-2008) [J].

Martinez-Cajas, Jorge L. ;

Pai, Nitika P. ;

Klein, Marina B. ;

Wainberg, Mark A. .

JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2009, 12

[23]

MILLER M, 2009, 16 C RETR OPP INF MO

[24] Analysis of natural sequence variation and covariation in human immunodeficiency virus type 1 integrase [J].

Myers, Richard E. ;

Pillay, Deenan .

JOURNAL OF VIROLOGY, 2008, 82 (18) :9228-9235

[25] Integrase inhibitors to treat HIV/AIDS [J].

Pommier, Y ;

Johnson, AA ;

Marchand, C .

NATURE REVIEWS DRUG DISCOVERY, 2005, 4 (03) :236-248

[26] HIV tropism:: diagnostic tools and implications for disease progression and treatment with entry inhibitors [J].

Poveda, Eva ;

Briz, Veronica ;

Quinones-Mateu, Miguel ;

Soriano, Vincent .

AIDS, 2006, 20 (10) :1359-1367

[27] In-Silico docking of HIV-1 integrase inhibitors reveals a novel drug type acting on an enzyme/DNA reaction intermediate [J].

Savarino, Andrea .

RETROVIROLOGY, 2007, 4

[28] HUMAN-IMMUNODEFICIENCY-VIRUS INTEGRATION PROTEIN EXPRESSED IN ESCHERICHIA-COLI POSSESSES SELECTIVE DNA CLEAVING ACTIVITY [J].

SHERMAN, PA ;

FYFE, JA .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (13) :5119-5123

[29] Broad Antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137) [J].

Shimura, Kazuya ;

Kodama, Eiichi ;

Sakagami, Yasuko ;

Matsuzaki, Yuji ;

Watanabe, Wataru ;

Yamataka, Kazunobu ;

Watanabe, Yasuo ;

Ohata, Yoshitsugu ;

Doi, Satoki ;

Sato, Motohide ;

Kano, Mitsuki ;

Ikeda, Satoru ;

Matsuoka, Masao .

JOURNAL OF VIROLOGY, 2008, 82 (02) :764-774

[30]

VACCA JWJ, 2007, 4 IAS C SYDN AUSTR

← 1 2 3 4 →